Administration of the active compound tetrahydroxystilbene glucoside (TSG) derived from the herb Polygonum multiflorum Thunb, reversed both overexpression of a-synuclein, a small protein found in the brain, and its accumulation using a mouse model of Alzheimer's disease.
These results may shed light on the neuropathology of AD and open up new avenues of treatment.
Aberrant accumulation of a-synuclein can form insoluble aggregates that have been implicated in several neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease (AD).
Researchers have now found that overexpression of a-synuclein increases with age and have demonstrated that a-synuclein aggregates in the hippocampus of older mice compared to normal controls.
"Our results raise the possibility that TSG might be a novel compound for the treatment of AD and dementia with Lewy body," co-lead investigator Lan Zhang, MD, PhD, Associate Professor, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Department of Pharmacology of Xuanwu Hospital of Capital Medical University in Beijing said.
The study used an animal model of AD: APPV717I transgenic (Tg) mice with the London mutation.
In previous work, the authors showed that these mice show cognitive impairments beginning at 4 months of age and develop amyloid plaques in the brain that are evident by 10 months.
In one series of experiments, 4 month old Tg mice were divided into 3 groups and received daily intragastric administration of distilled water (controls), low dose TSG (120 umol/kg/d), or high dose TSG (240 umol/kg/d). A fourth group consisted of age-matched non-Tg controls. The mice were treated until 10 months of age.
In a second series of experiments, 10-month-old mice were divided into similar control and TSG-treated groups and were treated for 6 months.
The authors used a variety of techniques to hone in on what was happening in the brains of the Tg mice compared to age-matched controls: cDNA microarray analysis, reverse transcription PCR, western blotting, and immunochemistry.
They found that a-synuclein messenger RNA (mRNA) and protein expression levels increase in a time-dependent manner in the hippocampus of Tg mice between ages 4 and 16 months and a-synuclein aggregation was noticeable at 16 months.
Age-related increases in a-synuclein were also seen in the control mice but to a lesser degree.
"We suggest that, besides increased AB (beta-amyloid) and amyloid plaques, overexpression and aggregation of a-synuclein in the hippocampus might partially account for cognitive impairment in this Tg mouse model of AD," comments co-lead investigator Lin Li, MD, PhD, Professor and Director, Department of Pharmacology, Xuanwu Hospital of Capital Medical University in Beijing.
She added that "a-synuclein overexpression occurs even in the early phase of AD and may accelerate AB production and deposition, which further facilitates a-synuclein overexpression and accumulation."
Analysis of the TSG-treated groups showed that TSG-treatment from the age of 4 to 10 months significantly downregulated a-synuclein mRNA and protein overexpression in the hippocampus of the Tg mice, and the effect was stronger at the higher dose.
This suggests that TSG may have a role in preventing the neurotoxic effects of a-synuclein on synaptic function and cell activity.
In addition, the finding that Tg reduced a-synuclein overexpression in older animals (>10 months) may indicate that it has therapeutic potential even after neuropathologic changes have occurred.
The findings are published in the journal Restorative Neurology and Neuroscience.